Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Capital Employed (2020 - 2025)

Foghorn Therapeutics has reported Return on Capital Employed over the past 6 years, most recently at 0.61% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.61% for Q4 2025, down 16.0% from a year ago — trailing twelve months through Dec 2025 was 0.61% (down 16.0% YoY), and the annual figure for FY2025 was 0.48%, down 1.0%.
  • Return on Capital Employed for Q4 2025 was 0.61% at Foghorn Therapeutics, up from 0.66% in the prior quarter.
  • Over the last five years, Return on Capital Employed for FHTX hit a ceiling of 0.23% in Q1 2022 and a floor of 0.66% in Q3 2025.
  • Median Return on Capital Employed over the past 5 years was 0.42% (2023), compared with a mean of 0.42%.
  • Biggest five-year swings in Return on Capital Employed: rose 23bps in 2022 and later fell -26bps in 2025.
  • Foghorn Therapeutics' Return on Capital Employed stood at 0.33% in 2021, then increased by 3bps to 0.32% in 2022, then tumbled by -39bps to 0.45% in 2023, then decreased by 0bps to 0.45% in 2024, then plummeted by -36bps to 0.61% in 2025.
  • The last three reported values for Return on Capital Employed were 0.61% (Q4 2025), 0.66% (Q3 2025), and 0.56% (Q2 2025) per Business Quant data.